Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 10/20 | 0.51 |
| ▸ | PPARG | P37231 | 10/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528161 | 1.00 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL2384187 | 1.00 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL2221136 | 0.90 | PPARG (0.61) | PPARAPPARGPPARDSRR | |
| SCHEMBL3861924 | 0.86 | PPARG (0.68) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL9686109 | 0.86 | ALDH1A1 (0.50) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL2037092 | 0.86 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL16672561 | 0.86 | ALDH1A1 (0.55) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL30893016 | 0.85 | PPARA (0.45) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL16672702 | 0.85 | LMNA (0.47) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL9902801 | 0.84 | L3MBTL1 (0.51) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621678-B | Antitumor compounds | 法马马有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117088871-A | Ring-fused compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-111253390-B | Ring-fused compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-114751920-A | Antitumor compounds | 法马马有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114736219-A | Antitumor compounds | 法马马有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111253390-A | Fused ring compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-110621678-A | Antitumor compounds | 法马马有限公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2003024920-A1 | SUBSTITUTED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | WO | disclosed |
| US-6486320-B2 | CONVERGENT SYNTHESIS STARTING FROM A 3-(AMINOMETHYL)QUINOLINE DERIVATIVE AND 5-HYDROXY-5-ETHYL-6-OXO-5,6-DIHYDROPYRANCARBOXYLIC ACID AND THE INTERMEDIATES OBTAINED. | AVENTIS PHARMA S.A. (FR) | 2002-11-26 | — | — | US | disclosed |
| CN-1373766-A | Phosphonic acid derivatives having carboxypeptidase B inhibitory activity | MEIJI SEIKA KAISHA (JP) | 2002-10-09 | — | — | CN | disclosed |
| US-20020045756-A1 | Preparation of camptothecin and of its derivatives | AVENTIS PHARMA S.A. | 2002-04-18 | — | — | US | disclosed |
| WO-2002022618-A1 | METHOD FOR PREPARING CAMPTOTHECIN AND ITS DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | WO | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-5028720-A | 6,7-nonsubstituted and 6,7-disubstituted-3,4-dihydroxy benzopyran-2H-one compounds having antiaggregatory properties and processes for their preparation | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1991-07-02 | — | — | US | disclosed |
| US-4874760-A | CALCIUM ANTAGONISTS | TOA EIYO, LTD. (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0277701-A1 | Thiazolopyridine derivative, their production and cardiovascular treating agents containing them | TOA EIYO LTD. (JP) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045756-A1 | Preparation of camptothecin and of its derivatives | ERCC5, TOP2A, DPYD | SLC1A3 1653/4885SLC1A2 2312/4885SLC1A1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.